Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6522-6530

  Attar, Ricardo M ^a,b   Jure Kunkel, Maria ^a   Balog, Aaron ^a   Cvijic, Mary Ellen ^a   Dell John, Janet ^a   Rizzo, Cheryl A ^a   Schweizer, Liang ^a   Spires, Thomas E ^a   Platero, J Suso ^a,b   Obermeier, Mary ^a   Shan, Weifang ^a   Salvati, Mark E ^a   Foster, William R ^a   Dinchuk, Joseph ^a   Chen, Shen Jue ^a   Vite, Gregory ^a   Kramer, Robert ^a   Gottardis, Marco M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BMS 641988; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER INHIBITION; CANCER RESISTANCE; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RAT; SEMINAL VESICLE; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BICYCLO COMPOUNDS, HETEROCYCLIC; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69249083981     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1111     Document Type: Article

References (50)

1. American Cancer Society. Cancer facts & figures 2008. Atlanta (GA): American Cancer Society; 2008.
2. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
3. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
4. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002;9:601-10.
5. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol 2006;175:27-34.
6. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
7. Taplin ME. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007;4:236-44.
8. Han G, Buchanan G, Ittmann M, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A 2005;102:1151-6.
9. Wu Y, Zhao W, Zhao J, et al. Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology 2007;148:2984-93.
10. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-77.
11. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69:16-22.
12. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606-14.
13. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
14. Halkidou K, Gnanapragasam VJ, Mehta PB, et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003;22:2466-77.
15. Zhang Y, Linn D, Liu Z, et al. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther 2008;7:3176-86.
16. Uemura M, Tamura K, Chung S, et al. Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81-6.
17. Aaronson DS, Muller M, Neves SR, et al. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol Cell Endocrinol 2007;270:50-6.
18. Schweizer L, Rizzo CA, Spires TE, et al. The androgen receptor can signal through Wnt/β-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol 2008;9:4.
19. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27:36-41.
20. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 2005;95:1327-35.
21. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10:309-19.
22. Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer 1994;30A:484-90.
23. Sramkoski RM, Pretlow TG II, Giaconia JM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-9.
24. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990;173: 534-40.
25. Heiser WC. Optimizing electroporation conditions for the transformation of mammalian cells. Methods Mol Biol 2000;130:117-34.
26. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996;271:7043-51.
27. Salvati ME, Balog A, Shan W, et al. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists. Bioorg Med Chem Lett 2008;18:1910-5.
28. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989;14:103-15.
29. Pretlow TG, Wolman SR, Micale MA, et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993;85:394-8.
30. Wainstein MA, He F, Robinson D, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994; 54:6049-52.
31. Tan J, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-9.
32. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991;145:313-8.
33. Ellis WJ, Vessella RL, Buhler KR, et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-48.
34. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
35. Bai G, Kasper S, Matusik RJ, Rennie PS, Moshier JA, Krongrad A. Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells. J Androl 1998;19:127-35.
36. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgenindependent C4-2 prostate cancer models. Prostate 2006;66:971-86.
37. Magee JA, Chang LW, Stormo GD, Milbrandt J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 2006; 147:590-8.
38. Nieto M, Finn S, Loda M, Hahn WC. Prostate cancer: re-focusing on androgen receptor signaling. Int J Biochem Cell Biol 2007;39:1562-8.
39. Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002;94:384-90.
40. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992;31:2393-9.
41. Taplin M-E, Bubley GJ, Ko Y-J, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-5.
42. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-53.
43. Yoshida T, Kinoshita H, Segawa T, et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005;65:9611-6.
44. Lamb DJ, Puxeddu E, Malik N, et al. Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl 2003;24:215-25.
45. Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998;34:61-72.
46. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003;169:1742-4.
47. Nakabayashi M, Regan MM, Lifsey D, et al. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 2005;96:783-6.
48. Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921-7.
49. Schaufele F, Chang CY, Liu W, et al. Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor. Mol Endocrinol 2000;14:2024-39.
50. Smitherman AB, Gregory CW, Mohler JL. Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft. Prostate 2003;57:24-31.